Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 202Recurrence 53Neoplasms, Plasma Cell 19Neoplasms 12Immunoglobulin Light-chain Amyloidosis 10Hematologic Diseases 4Amyloidosis 4Renal Insufficiency 3Lymphoma, Non-Hodgkin 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Hematologic Neoplasms 1Disease 1Corneal Diseases 1Alzheimer Disease 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 5Lenalidomide 4pomalidomide 3isatuximab 3Calcium Dobesilate 3Thalidomide 2Kidney Transplantation 2melflufen 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Zoledronic Acid 1Whole-Body Irradiation 1Tablets 1Ranitidine 1Plasmapheresis 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Drug Therapy 1Doxorubicin 1Diphenhydramine 1Data Collection 1Cyclosporine 1Bendamustine Hydrochloride 1BHQ880 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Renal Insufficiency × pomalidomide × Plasma cell × Clear all
NCT01575925 2022-11-04

POM Renal

Celgene

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡